Stada Group
Dr. Melanie Flick currently serves as the Manager of Global Regulatory Management at STADA Group since June 2019, while also working part-time as a Trainee in Financial Consultancy at SwissLife Select Oberhausen since March 2024. Previously, Dr. Flick held positions including Manager of Corporate Drug Regulatory Affairs - Scientific at MEDA Pharma GmbH & Co. KG and Regulatory Affairs Manager at betapharm Arzneimittel GmbH. Early career experience includes roles as a Clinical Trial Assistant at Venn Life Sciences and a Trainee at the Bundesinstitut für Arzneimittel und Medizinprodukte. Academic qualifications comprise a PhD in Natural Sciences from The University of Bonn, alongside Diplomas in Human and Molecular Biology and Biology from Universität des Saarlandes and RPTU Kaiserslautern-Landau, respectively. Additionally, Dr. Flick began as a Biological-technical Assistant at BBS Naturwissenschaften Ludwigshafen.
This person is not in any teams
This person is not in any offices
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.